Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 25-Aug-2017

HydrUStent

Abstract

HydrUStent is a Medtech company that offer a biodegradable medical device for urological disorders. Patients who have a ureteral stent require a second surgery for stent removal. Long implantation times, increase the problem of infection and encrustation, which becomes more severe when the stent is “forgotten” in the body. This is often due to lack of availability of the urologist or the patient's own move in the hospital. The crystal deposition on the surface of the stent and infections associated with these stents due to the excessive time may result in loss of the kidney or potentially even death. HydrUStent is a biodegradable, anti-bacterial urological stent, which eliminates the need for a second surgery, required nowadays for catheter removal. HydrUStent also avoids further complications from infections, due to its antibacterial properties. HydrUStent hydrogel degrades by dissolution of the material in urine avoiding crystal deposition. The dissolution profile is controlled and depending on the material used for stent production, the degradation rate can be tuned from 15 to 60 days of implantation, according to the specific treatment requirements.

Video

Original YouTube URL: Open

Introduction Video

Photos

Additional Questions

Who is your customer?

FOR patients who need temporary urological stents, WHO need to have a second surgery for stent removal, OUR PRODUCT is a degradable stent that will revolutionize the market, PROVIDING lower treatment cost, avoiding second surgery for stent removal, while reducing the risk of infection and eliminates the cases of “forgotten” stents.

What problem does this idea/product solve or what market need does it serve?

Patients who have a ureteral stent require a second surgery for stent removal. Long implantation times, increase the problem of infection and encrustation, which becomes more severe when the stent is “forgotten” in the body. This is often due to lack of availability of the urologist or the patient's own move in the hospital. The crystal deposition on the surface of the stent and infections associated with these stents due to the excessive time may result in loss of the kidney or potentially even death.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

HydrUStent is a biodegradable, anti-bacterial urological stent, which eliminates the need for a second surgery, required nowadays for catheter removal. HydrUStent also avoids further complications from infections, due to its antibacterial properties. HydrUStent hydrogel degrades by dissolution of the material in urine avoiding crystal deposition. The dissolution profile is controlled and depending on the material used for stent production, the degradation rate can be tuned from 15 to 60 days of implantation, according to the specific treatment requirements.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

The team includes a physician who knows what the problem is and has envisaged the solution for it. Dr. Estevão Lima is the urologist involved in the project and the Chief Medical Officer of the company. On the bench side, three researchers and Bussiness Development, Chief Executive Officer and the President and Chairman of the company, who come from the 3B’s Research Group, a leading group in the development of biomaterials for tissue engineering and regenerative medicine participated in the project. If the problem Dr. Lima’s patients face every day can be solved by developing a new biomaterial, we surely have the tools to do so. Ana Rita Duarte has been previously involved in different entrepreneurial programs promoted by COTEC Portugal. She is a 2.2 M€ ERC-granted researcher for exploring the next green solvents using natural deep eutectic solvents for chemical process engineering. Alexandre Barros is founder so far of 2 additional start-ups, inventor of 7 patents and has more than 10 years in the entrepreneurial community. Estevão Lima pioneered the application of minimally invasive surgical techniques and new technologies in Urology. He has received 14 research awards. He is a member of several international scientific societies such as the European Association of Urology, European Association for Transluminal Surgery and Endourological Society, where he is a part of the Education Committee and Professional Liaison Committee of the Urologic NOTES and LESS Working Group Rui L. Reis is the CEO of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine. He directs the correspondent European Economic Interest Group (EEIG), being the main office registered in Portugal. Rui L. Reis is the most productive Portuguese scientist ever in all fields of research. He is a member of 12 international research societies. He was selected as one of 100 most influential Portuguese citizens (in all areas of activity) by the respected EXPRESSO newspaper in 2013.